J. Durant

发表

Increased Time Exposure to Tenofovir Is Associated with a Greater Decrease in Estimated Glomerular Filtration Rate in HIV Patients with Kidney Function of Less than 60 ml/min/1.73 m2

V. Esnault, Jacques Durant, C. Pradier, 2012, Nephron Clinical Practice.

Erratum to ‘HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND)’

S. Chanalet, M. Ticchioni, C. Pradier, 2017, Heliyon.

HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND)

S. Chanalet, M. Ticchioni, C. Pradier, 2017, Heliyon.

Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH.

F. Dabis, M. Alvarez, J. Trinchet, 2012, Journal of hepatology.

Economic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV‐Infected Patients in the VIRADAPT Study

J. Schapiro, I. Durand-zaleski, P. Clevenbergh, 2000, Journal of acquired immune deficiency syndromes.

Effect of subinhibitory concentrations of cefamandole and cefuroxime on adherence ofStaphylococcus aureus andStaphylococcus epidermidis to polystyrene culture plates

P. Dellamonica, J. Entenza, J. Durant, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

Effects of subinhibitory concentrations of vancomycin and teicoplanin on adherence of staphylococci to tissue culture plates

C. Pradier, P. Dellamonica, J. Entenza, 1993, Antimicrobial Agents and Chemotherapy.

Phenotyping of Intrahepatic and Peripheral Blood Lymphocytes in Patients with Chronic Hepatitis C

J. Gugenheim, M. Ticchioni, A. Bernard, 1997, Digestive Diseases and Sciences.

Reduced incidence of kaposi's sarcoma and of systemic non‐hodgkin's lymphoma in HIV‐infected individuals treated with highly active antiretroviral therapy

D. Serraino, P. Piselli, M. Carrieri, 2003, International journal of cancer.

Possible prevention of in vitro selection of resistantStreptococcus pneumoniae by beta-lactamase inhibitors

C. Pradier, P. Dellamonica, F. Salvador, 1994, European Journal of Clinical Microbiology and Infectious Diseases.

In vitro development of resistance of Streptococcus pneumoniae to beta-lactam antibiotics.

C. Pradier, P. Dellamonica, J. Durant, 1995, Microbial drug resistance.

HIV Infection and Long‐Term Residual Cardiovascular Risk After Acute Coronary Syndrome

G. Finet, F. Duclos, J. Trochu, 2020, Journal of the American Heart Association.

Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort).

F. Dabis, M. Carrieri, B. Spire, 2013, Addiction.

Integrity of the NS5A (amino acid 2209 to 2248) region in hepatitis C virus 1b patients non-responsive to interferon therapy.

D. Ouzan, P. Halfon, M. Bourlière, 2000, Liver.

Long-Term Treatment with Lopinavir-Ritonavir Induces a Reduction in Peripheral Adipose Depots in Mice

Y. Le Marchand-Brustel, C. Perrin, M. Aouadi, 2006, Antimicrobial Agents and Chemotherapy.

Long-Term Treatment with Lopinavir-Ritonavir Induces a Reduction in Peripheral Adipose Depots in Mice (cid:1)

C. Perrin, M. Aouadi, Y. Marchand-Brustel, 2006 .

Long-Term Treatment with Lopinavir-Ritonavir Induces a Reduction in Peripheral Adipose Depots in Mice

Y. Le Marchand-Brustel, C. Perrin, M. Aouadi, 2006, Antimicrobial Agents and Chemotherapy.

Effect of Tipranavir/Ritonavir Combination on the Pharmacokinetics of Tadalafil in Healthy Volunteers

T. Macgregor, P. Dellamonica, N. Rouyrre, 2011, Journal of clinical pharmacology.

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial

Y. Yazdanpanah, P. Tebas, G. Pialoux, 2014, BMC Infectious Diseases.

In-vitro development of resistance to beta-lactam antibiotics in Streptococcus pneumoniae.

C. Pradier, P. Dellamonica, J. Durant, 1995, The Journal of antimicrobial chemotherapy.

An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients.

J. Grassi, C. Créminon, P. Dellamonica, 2004, Journal of immunological methods.

Sensitive Enzyme Immunoassay for Measuring Plasma and Intracellular Nevirapine Levels in Human Immunodeficiency Virus-Infected Patients

J. Grassi, C. Créminon, P. Dellamonica, 2004, Antimicrobial Agents and Chemotherapy.

AZT — does it prevent occurrence of salmonelloses in AIDS patients?

C. Pradier, M. Carles, P. Dellamonica, 1991, Journal of internal medicine.

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

Infliximab and human immunodeficiency virus infection: Viral load reduction and CD4+ T-cell loss related to apoptosis.

A. Bernard, S. Schneider, X. Hébuterne, 2006, Archives of internal medicine.

Early CD4(+) T cell recovery in human immunodeficiency virus-infected patients receiving effective therapy is related to a down-regulation of apoptosis and not to proliferation.

A. Pesce, A. Bernard, P. Clevenbergh, 2002, The Journal of infectious diseases.

The Role of Deranged Glucose Metabolism

A. Bernard, S. Benzaken, J. Breittmayer, 2017 .

High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patients.

D. Ouzan, P. Rampal, A. Tran, 1998, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Determination of ddATP Levels in Human Immunodeficiency Virus-Infected Patients Treated with Dideoxyinosine

R. Terreux, J. Vincent, P. Dellamonica, 2004, Antimicrobial Agents and Chemotherapy.

Persistence of Pneumocystis carinii after effective treatment of P. carinii pneumonia is not related to relapse or survival among patients infected with human immunodeficiency virus.

P. Dellamonica, P. Roger, P. Puglièse, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mycobacterial cutaneous manifestations: a new sign of immune restoration syndrome in patients with acquired immunodeficiency syndrome.

P. Dellamonica, P. Roger, J. Durant, 1999, Archives of dermatology.

Unusual cutaneous manifestations of miliary tuberculosis.

P. Dellamonica, C. Perrin, G. Bernardin, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hand edema and acrocyanosis: "puffy hand syndrome".

P. Dellamonica, J. Durant, P. Del giudice, 2006, Archives of dermatology.

Intestinal microsporidiosis due to Enterocytozoon bieneusi: a new case report in an AIDS patient.

J. Michiels, P. Dellamonica, R. Loubière, 1991, AIDS (London).

[Enterocytozoon bieneusi digestive microsporidiosis in 2 AIDS patients].

C. Pradier, J. Michiels, P. Dellamonica, 1991, Presse medicale.

Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial

J. Schapiro, C. Boucher, C. Boucher, 1999, The Lancet.

Measurement of the anti-HIV agent 2',3'-didehydro-2',3'-dideoxythymidine (D4T) by competitive ELISA.

B. Ferruà, J. Kubar, J. Durant, 1994, Journal of immunological methods.

Pefloxacin in the treatment of bone infections associated with foreign material.

P. Dellamonica, C. Argenson, J. Durant, 1990, The Journal of antimicrobial chemotherapy.

Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial

C. Pradier, I. Poizot-Martin, P. Dellamonica, 2010, AIDS care.

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results

P. Clevenbergh, P. Dellamonica, R. Garraffo, 2002, AIDS.

Persisting Long-Term Benefit of Genotype-Guided Treatment for HIV-Infected Patients Failing Haart. The Viradapt Study: Week 48 Follow-Up

J. Schapiro, C. Boucher, C. Boucher, 2000, Antiviral therapy.

Raltegravir-induced nephrolithiasis: a case report.

B. Dunais, J. Durant, A. Naqvi, 2012, AIDS.

Intracellular Concentration of Protease Inhibitors in HIV-1--Infected Patients: Correlation with MDR-1 Gene Expression and Low Dose of Ritonavir

S. Chaillou, P. Clevenbergh, P. Dellamonica, 2002, HIV clinical trials.

HIV Drug Resistance and Insufficient Drug Plasma Levels as Factors Determining Antiretroviral Treatment Failure

S. Chaillou, P. Clevenbergh, P. Dellamonica, 2001 .

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

J. Schapiro, P. Clevenbergh, P. Halfon, 2000, AIDS.

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

A. LaMarca, B. Clotet, C. Katlama, 2012, The Journal of infectious diseases.

Selection of the R263K mutation to dolutegravir in cerebrospinal fluid HIV-1 virus in one patient with HIV-associated neurocognitive disorders.

B. Dunais, J. Cottalorda, J. Durant, 2016, AIDS.

Efficacy of subinhibitory concentration of pefloxacin in preventing experimental Staphylococcus aureus foreign body infection in mice.

C. Pradier, P. Dellamonica, J. Entenza, 1992, Drugs under experimental and clinical research.

A case of gnathostomiasis in a European traveller returning from Mexico

P. Dellamonica, M. Grobusch, J. Durant, 2001, The British journal of dermatology.

Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study.

J. Schapiro, I. Durand-zaleski, P. Clevenbergh, 2000 .

Guillain-Barré syndrome associated with acute Q fever

M. Carles, P. Dellamonica, J. Durant, 1994, European Journal of Clinical Microbiology and Infectious Diseases.

Kinetics of disappearance of resistance mutations and reappearance of wild‐type during structured treatment interruptions

P. Clevenbergh, P. Halfon, H. Khiri, 2003, AIDS.

HIV-1 and persistent clinical latency, TAR element analysis and improved method for in vitro viral reactivation.

P. Dellamonica, J. Lesimple, D. March, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Simplification and First Validation of a Short Battery of Patient Questionnaires for Clinical Management of HIV-Infected Patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire®

B. Spire, B. Arnould, J. Gilquin, 2009, HIV clinical trials.

Microelimination or not? The changing epidemiology of HIV-HCV coinfection in France 2012-2018.

C. Charpentier, R. Tubiana, C. Katlama, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort Study

C. Sakarovitch, E. Fontas, P. Roger, 2015, PloS one.

Multimorbidity in Elderly Subjects according to the year of diagnosis of HIV-Infection - A Cross-Sectional DATAIDS Cohort Study.

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Apoptosis of naive CD4+ T-cells from HIV-infected patients with poor immune response to HAART is enhanced in vitro by steroid.

A. Pesce, M. Ticchioni, A. Bernard, 2004, The Journal of infection.

Efficacy and safety of Buxus sempervirens L. preparations (SPV(30)) in HIV-infected asymptomatic patients: a multicentre, randomized, double-blind, placebo-controlled trial.

S. Chamaret, L. Montagnier, P. Chantre, 1998, Phytomedicine : international journal of phytotherapy and phytopharmacology.

D rug-resistance genotyping in HIV-1 t h e r a py : the VIRAD A P T randomised controlled trial

J. Schapiro, P. Clevenbergh, P. Halfon, 2022 .

Variable Virological Outcomes According to the Center Providing Antiretroviral Therapy Within the PharmAdapt Clinical Trial

P. Clevenbergh, M. Bozonnat, P. Dellamonica, 2003, HIV clinical trials.

[Syphilis outbreak in southeast France].

J. Lacour, P. Dellamonica, J. Durant, 2006, Annales de dermatologie et de vénéréologie.

Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection.

V. Giordanengo, É. Rosenthal, B. Dunais, 2015, World journal of hepatology.

Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.

A. Horban, S. Ouwerkerk-Mahadevan, J. Sasadeusz, 2016, The Journal of antimicrobial chemotherapy.

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.

D. Podzamczer, C. Katlama, H. Furrer, 2012, The Journal of antimicrobial chemotherapy.

A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication

M. Ticchioni, Jacques Durant, C. Pradier, 2016, Journal of NeuroVirology.

[Second pregnancies in HIV-1-infected women. A prospective monocentric study].

F. Monpoux, S. De Smet, J. Delotte, 2008, Gynecologie, obstetrique & fertilite.

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

M. Ticchioni, C. Pradier, V. Biscay, 2014, AIDS.

COPD in HIV-Infected Patients: CD4 Cell Count Highly Correlated

Jacques Durant, C. Marquette, Elisa Demonchy, 2017, PloS one.

Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study

M. Ticchioni, C. Pradier, C. Lebrun-Frénay, 2013, Journal of NeuroVirology.

The suppression of immune activation during enfuvirtide‐based salvage therapy is associated with reduced CCR5 expression and decreased concentrations of circulating interleukin‐12 and IP‐10 during 48 weeks of longitudinal follow‐up

M. Ticchioni, M. Gougeon, P. Dellamonica, 2011, HIV medicine.

Hepatitis G Virus (HGV) and Antibodies to a Putative HGV Envelope Protein in Alcoholic Patients in South-Eastern France

D. Ouzan, P. Rampal, A. Tran, 1998, American Journal of Gastroenterology.

Lack of influence of hepatitis G virus infection on alcohol-related hepatic lesions.

D. Ouzan, P. Rampal, A. Tran, 1998, Scandinavian journal of gastroenterology.

Virologically suppressed patients with asymptomatic and symptomatic HIV‐associated neurocognitive disorders do not display the same pattern of immune activation

M. Ticchioni, Jacques Durant, C. Pradier, 2015, HIV medicine.

Prevention ofPneumocystis carinii pneumonia and of cerebral toxoplasmosis by roxithromycin in HIV-infected patients

J. Pechère, M. Carles, P. Dellamonica, 2006, Infection.

Pharmacokinetic parameters and killing rates in serum of volunteers receiving amoxicillin, cefadroxil or cefixime alone or associated with niflumic acid or paracetamol

R. Farinotti, P. Dellamonica, B. Rouveix, 1998, European Journal of Drug Metabolism and Pharmacokinetics.

Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients

F. Clavel, P. Clevenbergh, J. Schmit, 2002, HIV clinical trials.

Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.

J. Izopet, F. Raffi, F. Lucht, 2016, The Journal of antimicrobial chemotherapy.

In Vivo Comparative Pharmacokinetics and Pharmacodynamics of Moxifloxacin and Levofloxacin in Human Neutrophils

P. Dellamonica, B. Dunais, J. Durant, 2005, Clinical drug investigation.

[Treatment with clarithromycin of 173 HIV+ patients with disseminated Mycobacterium avium intracellulare infection].

B. Dautzenberg, J. Reynes, C. Truffot, 1994, Revue des maladies respiratoires.

Anti-GOR and anti-thyroid autoantibodies in patients with chronic hepatitis C.

D. Ouzan, A. Tran, S. Benzaken, 1995, Clinical Immunology and Immunopathology.

Significance of serum immunoglobulin M to hepatitis C virus core in patients with chronic hepatitis C.

J Durant, A Rampal, P. Rampal, 1997, The American journal of gastroenterology.

Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study.

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2020, The Journal of antimicrobial chemotherapy.

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

C. Katlama, Y. Yazdanpanah, C. Blanco-Betancourt, 2017, HIV medicine.

Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.

C. Katlama, P. Muret, C. Solas, 2012, The Journal of antimicrobial chemotherapy.

Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT’AIDS cohort

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2019, BMC Infectious Diseases.

No barrier to care, yet disparities in the HIV care continuum in France: a nationwide population study.

C. Katlama, Y. Yazdanpanah, E. Delaporte, 2021, Journal of Antimicrobial Chemotherapy.

Apoptosis and proliferation kinetics of T cells in patients having experienced antiretroviral treatment interruptions.

S. Chaillou, M. Ticchioni, A. Bernard, 2003, The Journal of antimicrobial chemotherapy.

Prevalence of and factors associated with depression among people living with HIV in France

F. Marion, M. Duracinsky, F. Lert, 2017, HIV medicine.

[Visceral leishmaniasis resistant to conventional treatments: value of amphotericin B].

P. Dellamonica, J. Quaranta, J. Durant, 1993, Pathologie et biologie.